MORETTI, ERICA

MORETTI, ERICA  

Scienze Biomediche, Sperimentali e Cliniche 'Mario Serio'  

Mostra records
Risultati 1 - 20 di 22 (tempo di esecuzione: 0.036 secondi).
Titolo Data di pubblicazione Autore(i) File
Adjuvant chemotherapy: which patient? What regimen? 2013 Turner N; Biganzoli L; Malorni L; Migliaccio I; Moretti E; Pestrin M; Sanna G; Siclari O; Di Leo A.
Adjuvant systemic treatment for individual patients with triple negative breast cancer 2011 Oakman C; Moretti E; Galardi F; Biagioni C; Santarpia L; Biganzoli L; Di Leo A
Anthracyclines: the first generation of cytotoxic targeted agents? A possible dream 2008 Di Leo A; Moretti E
Can we use anthracyclines as targeted agents?. 2009 Di Leo A; Moretti E
Fulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancer 2011 Oakman C; Moretti E; Santarpia L; Di Leo A
Management of Aromatase Inhibitor-Resistant Disease with Estrogen, Selective Estrogen Receptor Down-Regulators, and Other Agents 2011 Oakman C; Santarpia L; Moretti E; Biganzoli L; Di Leo A
Patients with triple negative breast cancer. 2011 Di Leo A; Oakman C; Moretti E; Galardi F; Biagioni C; Santarpia
Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. 2012 Jung EJ; Santarpia L; Kim J; Esteva FJ; Moretti E; Buzdar AU; Di Leo A; Le XF; Bast RC Jr; Park ST; Pusztai L; Calin GA
Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TREnd Trial 2020 Amelia McCartney; Martina Bonechi; Francesca De Luca; Chiara Biagioni; Giuseppe Curigliano; Erica Moretti; Alessandro Marco Minisini; Mattias Bergqvist; Matteo Benelli; Ilenia Migliaccio; Francesca Galardi; Emanuela Risi; Irene De Santo; Dario Romagnoli; Laura Biganzoli; Angelo Di Leo; Luca Malorni
Predicting anthracycline benefit: have we made any progress? 2009 Moretti E; Oakman C; Di Leo A
Predictive molecular markers of anthracycline effectiveness in early breast cancer 2011 Di Leo A; Moretti E; Oakman C; Biganzoli L; Santarpia L
Re-searching anthracycline therapy 2010 Oakman C; Moretti E; Di Leo A
Re: Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy 2009 Oakman C; Moretti E; Sotiriou C; Viale G; Di Leo A
Risk assessment of disease recurrence in early breast cancer: A serum metabolomic study focused on elderly patients 2023 Risi, Emanuela; Lisanti, Camilla; Vignoli, Alessia; Biagioni, Chiara; Paderi, Agnese; Cappadona, Silvia; Monte, Francesca Del; Moretti, Erica; Sanna, Giuseppina; Livraghi, Luca; Malorni, Luca; Benelli, Matteo; Puglisi, Fabio; Luchinat, Claudio; Tenori, Leonardo; Biganzoli, Laura
Targeting triple negative breast cancer: is p53 the answer? 2013 Turner N; Moretti E; Siclari O; Migliaccio I; Santarpia L; D'Incalci M; Piccolo S; Veronesi A; Zambelli A; Del Sal G; Di Leo A
Targeting triple negative breast cancer: is p53 the answer? 2013 Turner, Natalie; Moretti, Erica; Siclari, Olimpia; Migliaccio, Ilenia; Santarpia, Libero; D'Incalci, Maurizio; Piccolo, Stefano; Veronesi, Andrea; Zambelli, Alberto; Del Sal, Gianni; Di Leo, Angelo
Taxanes in the elderly: Can we gain as much and be less toxic? 2009 Biganzoli L; Licitra S; Moretti E; Pestrin M; Zafarana E; Di Leo A
The continued evidence from overviews: What is the clinical utility? 2013 Turner N; Biganzoli L; Malorni L; Migliaccio I; Moretti E; Pestrin M; Sanna G; Siclari O; Di Leo A
The role of topoisomerase II alpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients 2009 Oakman C; Moretti E; Galardi F; Santarpia L; Di Leo A
TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer. 2013 -Moretti E; Desmedt C; Biagioni C; Regan MM; Oakman C; Larsimont D; Galardi F; Piccart-Gebhart M; Sotiriou C; Rimm DL; Di Leo A